Suppr超能文献

发现大环内酯类抗生素对多种耐药革兰氏阴性病原体有效。

Discovery of Macrolide Antibiotics Effective against Multi-Drug Resistant Gram-Negative Pathogens.

机构信息

Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138, United States.

Zikani Therapeutics, 480 Arsenal Way, Watertown, Massachusetts 02472, United States.

出版信息

Acc Chem Res. 2021 Apr 6;54(7):1635-1645. doi: 10.1021/acs.accounts.1c00020. Epub 2021 Mar 10.

Abstract

Macrolides are among the most widely prescribed antibiotics, particularly for bacterial lung infections, due to their favorable safety, oral bioavailability, and spectrum of activity against Gram-positive pathogens such as , the most common cause of bacterial pneumonia. Their utility against Gram-negative bacteria is extremely limited and does not include the Enterobacteriaceae or other ESKAPE pathogens. With the increasing development of resistance to current therapies and the lack of safe, oral options to treat Gram-negative infections, extended-spectrum macrolides have the potential to provide valuable treatment options. While the bacterial ribosome, the target of macrolides, is highly conserved across Gram-positive and Gram-negative bacteria, traditional macrolides do not possess the proper physicochemical properties to cross the polar Gram-negative outer membrane and are highly susceptible to efflux. As with most natural product-derived compounds, macrolides are generally prepared through semisynthesis, which is limited in scope and lacks the ability to make the drastic physicochemical property changes necessary to overcome these hurdles.By using a fully synthetic platform technology to greatly expand structural diversity, novel macrolides were prepared with a focus on lowering the MW and increasing the polarity to achieve a physicochemical property profile more similar to that of traditional Gram-negative drug classes. In addition to the removal of lipophilic groups, a critical structural feature for obtaining Gram-negative activity in the macrolide class proved to be the introduction of small secondary or tertiary amines to yield polycationic species potentially capable of self-promoted uptake. Within the azithromycin-like 15-membered azalides, potent activity was seen when small alkyl amines were introduced at the 6'-position of desosamine. The biggest gains, however, were made by replacing the entire C10-C13 fragment of the macrolactone ring with commercially available or readily synthesized 1,2-aminoalcohols, leading to 13-membered azalides. The introduction of a tethered basic amine at the C10-position and systematic optimization of substitution and tether length and flexibility ultimately provided new macrolides that for the first time exhibit clinically relevant antibacterial activity against multi-drug resistant Gram-negative bacteria. A retrospective computational analysis of >1800 fully synthetic macrolides prepared during this effort identified key drivers and optimum ranges for improving permeability and avoiding efflux. In contrast to standard Gram-negative drugs which generally have MWs below 600 and clogD values below 0, we found that the ideal ranges for Gram-negative macrolides were MW between 600 and 720 and cLogD between -1 and 3. A total charge of between 2.5 and 3 was also required to provide optimal permeability and efflux avoidance. Thus, Gram-negative macrolides occupy a unique physicochemical property space that lies between traditional Gram-negative drug classes and Gram-positive macrolides.

摘要

大环内酯类抗生素是应用最广泛的抗生素之一,尤其适用于治疗细菌性肺部感染,这主要是因为它们具有良好的安全性、口服生物利用度以及对革兰氏阳性病原体(如肺炎链球菌,这是细菌性肺炎最常见的病原体)的作用谱。它们对革兰氏阴性菌的作用非常有限,不包括肠杆菌科或其他 ESKAPE 病原体。随着当前治疗方法耐药性的不断发展,以及缺乏安全的口服药物来治疗革兰氏阴性菌感染,因此,新型大环内酯类药物具有提供有价值的治疗选择的潜力。虽然细菌核糖体是大环内酯类抗生素的靶点,但其在革兰氏阳性菌和革兰氏阴性菌中高度保守,但传统的大环内酯类抗生素没有适当的物理化学特性来穿过极性的革兰氏阴性外膜,并且极易被外排。与大多数天然产物衍生的化合物一样,大环内酯类抗生素通常通过半合成制备,其范围有限,并且缺乏进行必要的剧烈物理化学性质变化以克服这些障碍的能力。通过使用完全合成的平台技术来极大地扩展结构多样性,我们专注于降低分子量和增加极性,以获得更类似于传统革兰氏阴性药物类别的物理化学特性。除了去除亲脂性基团外,在大环内酯类药物中获得革兰氏阴性活性的一个关键结构特征是引入小的仲或叔胺,以产生潜在能够自我促进摄取的聚阳离子物种。在类似阿奇霉素的 15 元氮杂内酯中,当在去甲糖胺的 6'位引入小烷基胺时,观察到了很强的活性。然而,最大的收益是通过用市售或易于合成的 1,2-氨基醇替换大环内酯环的整个 C10-C13 片段来实现的,这导致了 13 元氮杂内酯的产生。在 C10 位引入连接的碱性胺,并对取代和连接体长度和灵活性进行系统优化,最终提供了新的大环内酯类药物,这些药物首次表现出针对多药耐药革兰氏阴性菌的临床相关抗菌活性。对在此项研究中制备的>1800 种全合成大环内酯类化合物进行的回顾性计算分析确定了改善通透性和避免外排的关键驱动因素和最佳范围。与通常分子量低于 600 和 clogD 值低于 0 的标准革兰氏阴性药物不同,我们发现革兰氏阴性大环内酯类药物的理想范围是分子量在 600 到 720 之间,cLogD 值在-1 到 3 之间。还需要总电荷为 2.5 到 3,以提供最佳的通透性和避免外排。因此,革兰氏阴性大环内酯类药物占据了独特的物理化学性质空间,位于传统的革兰氏阴性药物类和革兰氏阳性大环内酯类药物之间。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验